Pharmacogenetic approach for cancer treatment-tailored medicine in practice

Yoshinori Hasegawa; Yuichi Ando; Maki Ando; Naozumi Hashimoto; Kazuyoshi Imaizumi; Kaoru Shimokata

doi:10.1196/annals.1377.020

Pharmacogenetic approach for cancer treatment-tailored medicine in practice

Yoshinori Hasegawa
, Yuichi Ando
, Maki Ando
, Naozumi Hashimoto
, Kazuyoshi Imaizumi
, Kaoru Shimokata

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

18 Citations (Scopus)

Abstract

This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is clinically useful and important for predicting and avoiding related toxicities. On the basis of these backgrounds, the irinotecan label was updated in 2005 in the United States to provide pharmacogenetic information, and a dose reduction of irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele when administered in combination with other agents or a single agent. The irinotecan/UGT1A1 issue and the development of molecular diagnostic testing are now to be translated into clinical practice.

Original language	English
Title of host publication	Integrated Molecular Medicine for Neuronal and Neoplastic Disorders
Publisher	Blackwell Publishing Inc.
Pages	223-232
Number of pages	10
ISBN (Print)	1573316555, 9781573316552
DOIs	https://doi.org/10.1196/annals.1377.020
Publication status	Published - 11-2006
Externally published	Yes

Publication series

Name	Annals of the New York Academy of Sciences
Volume	1086
ISSN (Print)	0077-8923
ISSN (Electronic)	1749-6632

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

General Neuroscience
General Biochemistry,Genetics and Molecular Biology
History and Philosophy of Science

Access to Document

10.1196/annals.1377.020

Cite this

Hasegawa, Y., Ando, Y., Ando, M., Hashimoto, N., Imaizumi, K., & Shimokata, K. (2006). Pharmacogenetic approach for cancer treatment-tailored medicine in practice. In Integrated Molecular Medicine for Neuronal and Neoplastic Disorders (pp. 223-232). (Annals of the New York Academy of Sciences; Vol. 1086). Blackwell Publishing Inc.. https://doi.org/10.1196/annals.1377.020

@inproceedings{8ae0c0419d4b4800b38a59747ad3a478,

title = "Pharmacogenetic approach for cancer treatment-tailored medicine in practice",

abstract = "This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is clinically useful and important for predicting and avoiding related toxicities. On the basis of these backgrounds, the irinotecan label was updated in 2005 in the United States to provide pharmacogenetic information, and a dose reduction of irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele when administered in combination with other agents or a single agent. The irinotecan/UGT1A1 issue and the development of molecular diagnostic testing are now to be translated into clinical practice.",

keywords = "Chemotherapy, Gene polymorphism, Irinotecan, UGT1A1",

author = "Yoshinori Hasegawa and Yuichi Ando and Maki Ando and Naozumi Hashimoto and Kazuyoshi Imaizumi and Kaoru Shimokata",

year = "2006",

month = nov,

doi = "10.1196/annals.1377.020",

language = "English",

isbn = "1573316555",

series = "Annals of the New York Academy of Sciences",

publisher = "Blackwell Publishing Inc.",

pages = "223--232",

booktitle = "Integrated Molecular Medicine for Neuronal and Neoplastic Disorders",

}

Pharmacogenetic approach for cancer treatment-tailored medicine in practice. / Hasegawa, Yoshinori; Ando, Yuichi; Ando, Maki et al.
Integrated Molecular Medicine for Neuronal and Neoplastic Disorders. Blackwell Publishing Inc., 2006. p. 223-232 (Annals of the New York Academy of Sciences; Vol. 1086).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

TY - GEN

T1 - Pharmacogenetic approach for cancer treatment-tailored medicine in practice

AU - Hasegawa, Yoshinori

AU - Ando, Yuichi

AU - Ando, Maki

AU - Hashimoto, Naozumi

AU - Imaizumi, Kazuyoshi

AU - Shimokata, Kaoru

PY - 2006/11

Y1 - 2006/11

N2 - This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is clinically useful and important for predicting and avoiding related toxicities. On the basis of these backgrounds, the irinotecan label was updated in 2005 in the United States to provide pharmacogenetic information, and a dose reduction of irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele when administered in combination with other agents or a single agent. The irinotecan/UGT1A1 issue and the development of molecular diagnostic testing are now to be translated into clinical practice.

AB - This article focuses on pharmacogenetic associations between genetic polymorphism of uridine diphosphate glucuronosyltransferase (UGT) 1A1 gene and irinotecan toxicity. Accumulating evidence provides support to the idea that determination of UGT1A1 polymorphisms before irinotecan treatment is clinically useful and important for predicting and avoiding related toxicities. On the basis of these backgrounds, the irinotecan label was updated in 2005 in the United States to provide pharmacogenetic information, and a dose reduction of irinotecan should be considered for patients known to be homozygous for the UGT1A1*28 allele when administered in combination with other agents or a single agent. The irinotecan/UGT1A1 issue and the development of molecular diagnostic testing are now to be translated into clinical practice.

KW - Chemotherapy

KW - Gene polymorphism

KW - Irinotecan

KW - UGT1A1

UR - https://www.scopus.com/pages/publications/34447288110

UR - https://www.scopus.com/pages/publications/34447288110#tab=citedBy

U2 - 10.1196/annals.1377.020

DO - 10.1196/annals.1377.020

M3 - Conference contribution

C2 - 17185519

AN - SCOPUS:34447288110

SN - 1573316555

SN - 9781573316552

T3 - Annals of the New York Academy of Sciences

SP - 223

EP - 232

BT - Integrated Molecular Medicine for Neuronal and Neoplastic Disorders

PB - Blackwell Publishing Inc.

ER -

Pharmacogenetic approach for cancer treatment-tailored medicine in practice

Abstract

Publication series

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this